Get the Stockscreener App
19.93
4.00%
-0.83
Pre-market:
22.50
2.57
+12.90%
Odyssey Therapeutics Inc stock is traded at $19.93, with a volume of 396.00K.
It is down -4.00% in the last 24 hours and down -20.76% over the past month.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
See More
Previous Close:
$20.76
Open:
$20.77
24h Volume:
396.00K
Relative Volume:
1.43
Market Cap:
$957.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-6.4396
EPS:
-3.0949
Net Cash Flow:
-
1W Performance:
-14.17%
1M Performance:
-20.76%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$18.77
$21.09
1-Week Range:
$18.77
$25.22
52-Week Range:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Name
Odyssey Therapeutics Inc
Sector
Industry
Phone
(212) 841-1000
Address
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
19.93 | 957.81M | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Stock (ODTX) Latest News
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway By Investing.com - Investing.com Canada
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway - Investing.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P Global BMI Index - marketscreener.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to Russell 3000 Growth Benchmark - marketscreener.com
A biotech presentation is set for Sept. 23. Odyssey Therapeutics will take part online. - Stock Titan
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply - finance.yahoo.com
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.ca
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Eastern Progress
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - MarketBeat
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target - finance.yahoo.com
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - theglobeandmail.com
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - MarketBeat
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Inc Stock (ODTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):